Expanding Portfolio

Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis

Colin Kerr

Published: Friday, February 1, 2019

Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis. The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials. Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.” www.oculis.com

Tags: anti-TNF alpha antibody, ophthalmic disease

Latest Articles

Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Update on Astigmatism Analysis

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

iNovation Innovators Den Boosts Eye Care Pioneers

New ideas and industry, colleague, and funding contacts among the benefits.

From Concept to Clinic

Partnerships with academia and industry promote innovation.

José Güell: Trends in Cornea Treatment

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.